| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 1374887593.5 | 1255495637.6 | 1033864143.1 |
| Other income | 17475576.9 | 15826052.5 | 29876825.3 |
| Total income | 1392363170.5 | 1271321690.1 | 1063740968.3 |
| Profit before exceptional items & tax | 257784452.6 | 220419558.5 | 164435184.0 |
| Profit before tax | 257784452.6 | 220419558.5 | 164435184.0 |
| Net profit | 185507074.8 | 158018248.3 | 122179453.8 |
| Operating margin | 18.5% | 17.3% | 15.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +51.80% |
|---|---|
| Net profit, quarter on quarter | +17.40% |
| Revenue, year on year | +33.00% |
| Operating profit, year on year | +78.60% |
| Operating profit, quarter on quarter | +17.50% |
NSE results filing, NSE: BETA. Figures extracted from the filing.
Beta Drugs Ltd: key numbers
- Share price
- ₹1,976.80
- Market cap
- ₹2,191 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 42.2×Sector 46.1×
- Promoter holding
- 58.91%-0.19% QoQ
- FII holding
- 1.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Other Announcement
Beta Drugs Limited submitted its quarterly Statement of Deviation or Variation for the preferential issue proceeds, confirming no deviation from the stated objects.
Beta Drugs Earnings Call Transcript: Key Takeaways
Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.
- Call
- Guides 25% growth
Beta Drugs Investor Presentation: Key Takeaways
Beta Drugs reported H1 FY27 revenue of INR 263 Cr with EBITDA margins expanding to 23.2%. The firm is transitioning from a CMO to a branded specialty oncology powerhouse.
Beta Drugs Board Meeting Date
Beta Drugs Limited notified the exchange of a board meeting scheduled for 22-Oct-2026 to consider quarterly financial results. The trading window closure was also intimated.
Beta Drugs Annual General Meeting
Beta Drugs Limited conducted its 21st Annual General Meeting on September 30, 2026. Shareholders considered resolutions including financial statement adoption, director re-appointments, and auditor ratification.
Beta Drugs Business Update
Beta Drugs secured Azerbaijani regulatory approvals for its oncology portfolio across multiple dosage forms. The company targets Azerbaijan commercialisation during the current financial year.